Covid 19 Research using Clinical Trials (Home Page)
SelinexorWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
|
Name (Synonyms) |
Correlation |
drug3101 | WHO recommendations (waiting condition) Wiki | 0.71 |
drug1205 | Guided online support program Wiki | 0.71 |
drug2385 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki | 0.50 |
drug2122 | Placebo Wiki | 0.07 |
Correlated MeSH Terms (4)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There are 2 clinical trials
Clinical Trials
The main purpose of this study is to evaluate the activity of low dose oral selinexor
(KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization
and the rate of morbidity and mortality in participants with severe COVID-19 compared to
placebo.
Primary Outcomes
Measure: Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale Time: Baseline to Day 14
Secondary Outcomes
Measure: Time to Clinical Improvement (TTCI) Time: Up to Day 28
Measure: Overall Death Rate Time: Day 14, Day 28
Measure: Rate of Mechanical Ventilation Time: Up to Day 28
Measure: Time to Mechanical Ventilation Time: Up to Day 28
Measure: Overall Survival Time: Up to Day 28
Measure: Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale Time: Baseline, Day 28
Measure: Time to Intensive Care Unit (ICU) Admission Time: Up to Day 28
Measure: Rate of Intensive Care Unit (ICU) Admission Time: Up to Day 28
Measure: Length of Stay in Hospital Time: Up to Day 28
Measure: Percentage of Participants Discharged from Hospital Time: Up to Day 28
Measure: Length of Stay in Intensive Care Unit (ICU) Time: Up to Day 28
Measure: Duration of Oxygen Supplementation Time: Up to Day 28
Measure: Duration of Mechanical Ventilation Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants ≤ 70 Years Old Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants > 70 Years Old Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants with Pre-existing Diseases Time: Up to Day 28
Measure: Change in Oxygenation Index Time: Up to Day 28
Measure: Time to Improvement of One Point Using WHO Ordinal Scale Improvement Time: Up to Day 28
Measure: Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point Time: Up to Day 28
Measure: Change from Baseline in C-reactive protein (CRP) Levels Time: Up to Day 28
Measure: Change from Baseline in Ferritin Levels Time: Up to Day 28
Measure: Change from Baseline in Lactate Dehydrogenase (LDH) Levels Time: Up to Day 28
Measure: Changes from Baseline in Blood Plasma Cytokines Levels Time: Up to Day 28
Measure: Number of Participants with Adverse Events (AE) Time: From start of study drug administration up to Day 28
2 A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19
The main purpose of this study is to evaluate the activity, safety and reduction in mortality
of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
NCT04355676 Coronavirus Infection Drug: Selinexor MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome
Primary Outcomes
Measure: Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale Time: Baseline to Day 14
Secondary Outcomes
Measure: Time to Clinical Improvement (TTCI) Time: Up to Day 28
Measure: Overall Death Rate Time: Day 14, Day 28
Measure: Rate of Mechanical Ventilation Time: Up to Day 28
Measure: Time to Mechanical Ventilation Time: Up to Day 28
Measure: Overall Survival Time: Up to Day 28
Measure: Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale Time: Up to Day 28
Measure: Time to Intensive Care Unit (ICU) Admission Time: Up to Day 28
Measure: Rate of Intensive Care Unit (ICU) Admission Time: Up to Day 28
Measure: Length of Stay in Hospital Time: Up to Day 28
Measure: Percentage of Participants Discharged From Hospital Time: Up to Day 28
Measure: Length of Stay in Intensive Care Unit (ICU) Time: Up to Day 28
Measure: Duration of Oxygen Supplementation Time: Up to Day 28
Measure: Duration of Mechanical Ventilation Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants ≤ 70 Years Old Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants > 70 Years Old Time: Up to Day 28
Measure: Time to Clinical Improvement in Participants with Pre-existing Diseases Time: Up to Day 28
Measure: Change in Oxygenation Index Time: Up to Day 28
Measure: Time to Improvement of One Point Using WHO Ordinal Scale Improvement Time: Up to Day 28
Measure: Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point Time: Up to Day 28
Measure: Change from Baseline in C-reactive protein (CRP) Levels Time: Up to Day 28
Measure: Change from Baseline in Ferritin Levels Time: Up to Day 28
Measure: Change from Baseline in Lactate Dehydrogenase (LDH) Levels Time: Up to Day 28
Measure: Number of Participants with Adverse Events (AE) Time: From start of study drug administration up to follow-up (Day 30)
No related HPO nodes (Using clinical trials)